Page 68 - Drug Class Review
P. 68
Page 64 of 205
Drug Effectiveness Review Project
To investigate the efficacy and tolerability of two different dosages of RIV in elderly patients with
placebo N/A 13 weeks 133
rivastigmine 6 mg/d 13 weeks 133 Diagnosis of mild-to-moderate dementia using DSM-IV and DSM-III-R criteria and diagnosis of Medications for non-cognitive aspects of AD such as hypnotics provided they were not long-acting agents; drugs for other concomitant conditions at continued dosage
Drugs Authors: Agid et al. 56 Country: Multinational Setting: Multi-center (Europe, 54 centers) rivastigmine 4 mg/d 13 weeks 136 probable AD according to NINCDS/ADRDA criteria
Alzheimer Year: 1998 Novartis Pharma AG probable AD Study design: RCT Sample size: 402 NR
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
